Gadani Sameer, Partovi Sasan, Levitin Abraham, Zerona Nicholas, Sengupta Shreya, D'Amico Giuseppe, Diago Uso Teresa, Menon K V Narayanan, Quintini Cristiano
Imaging Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Cardiovasc Diagn Ther. 2022 Feb;12(1):135-146. doi: 10.21037/cdt-21-98.
This paper examines the incidence, clinical presentation, and pathophysiology of portal vein thrombosis (PVT) in cirrhosis. Additionally, we have reviewed the literature regarding the current status of medical and interventional radiology management of PVT and have proposed a novel algorithm for the management given different clinical scenarios. Lastly two representative cases displaying endovascular treatment options are provided.
Portal vein thrombus in the setting of cirrhosis is an increasingly recognized clinical issue with debate on its pathophysiology, natural course, and optimal treatment. Approximately one-third of patients are asymptomatic, and detection of the thrombus is an incidental finding on imaging performed for other reasons. In 30% to 50% of patients, PVT resolves spontaneously. However, there is increased post-transplant mortality in patients with completely occlusive PVT, therefore effective early revascularization strategies are needed for patients with complete PVT who are expected to undergo liver transplant. Additionally, no consensus has been reached regarding PVT treatment in terms of timing and type of interventions as well as type and duration of anticoagulation.
Computerized literature search as well as discussion with experts in the field.
Management of PVT is complex, as many variables affect which treatments can be used. Anticoagulation appears to be the optimal first-line treatment in patients with acute PVT but without bleeding varices or mesenteric ischemia. Minimally invasive treatments include various methods of mechanical thrombectomy, chemical thrombolysis, and transjugular intrahepatic portosystemic shunt (TIPS) placement with or without variceal embolization. Definitive recommendations are difficult due to lack of high quality data and continued research is needed to evaluate the efficacy of different anticoagulants as well as the timing and use of various minimally invasive therapies in specific circumstances.
本文研究肝硬化患者门静脉血栓形成(PVT)的发病率、临床表现及病理生理学。此外,我们回顾了有关PVT的药物治疗和介入放射学管理现状的文献,并针对不同临床情况提出了一种新的管理算法。最后提供了两个展示血管内治疗方案的代表性病例。
肝硬化患者的门静脉血栓是一个日益受到关注的临床问题,其病理生理学、自然病程和最佳治疗方法存在争议。约三分之一的患者无症状,血栓是在因其他原因进行的影像学检查中偶然发现的。30%至50%的患者PVT可自发缓解。然而,完全闭塞性PVT患者移植后死亡率增加,因此对于预期进行肝移植的完全性PVT患者,需要有效的早期血管再通策略。此外,在PVT治疗的时机和干预类型以及抗凝的类型和持续时间方面尚未达成共识。
计算机文献检索以及与该领域专家进行讨论。
PVT的管理很复杂,因为许多变量会影响可采用的治疗方法。抗凝似乎是急性PVT但无静脉曲张出血或肠系膜缺血患者的最佳一线治疗方法。微创治疗包括各种机械血栓切除术、化学溶栓以及经颈静脉肝内门体分流术(TIPS)放置术(有无静脉曲张栓塞)。由于缺乏高质量数据,难以给出明确建议,需要持续研究以评估不同抗凝剂的疗效以及各种微创治疗在特定情况下的时机和应用。